<?xml version="1.0" encoding="UTF-8"?>
<p id="p0545">Rosenberg et al.
 <xref rid="b1310" ref-type="bibr">
  <sup>262</sup>
 </xref> in mid-March 2020, verified the efficacy of HCQ with and without azithromycin in a Retrospective multicentre cohort study with COVID-19 patients in New York. The study monitored the application of these drugs until April 24th, considering pre-existing conditions, clinical conditions on admission, results and adverse effects reported on medical records. It was verified that from the 1.438 admissions, only patients who received HQ exclusively, or Azithromycin exclusively, or both drugs had greater chances of developing diabetes than control group. Mortality rate did not show significant difference when the drugs were used either in isolation or combined or when no medication was administered.
</p>
